74 related articles for article (PubMed ID: 7636241)
1. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation.
Zhu Z; Carter P
J Immunol; 1995 Aug; 155(4):1903-10. PubMed ID: 7636241
[TBL] [Abstract][Full Text] [Related]
2. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
[TBL] [Abstract][Full Text] [Related]
3. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.
Woodle ES; Thistlethwaite JR; Jolliffe LK; Zivin RA; Collins A; Adair JR; Bodmer M; Athwal D; Alegre ML; Bluestone JA
J Immunol; 1992 May; 148(9):2756-63. PubMed ID: 1533410
[TBL] [Abstract][Full Text] [Related]
4. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
Bolt S; Routledge E; Lloyd I; Chatenoud L; Pope H; Gorman SD; Clark M; Waldmann H
Eur J Immunol; 1993 Feb; 23(2):403-11. PubMed ID: 8436176
[TBL] [Abstract][Full Text] [Related]
5. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
6. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells.
Zhu Z; Lewis GD; Carter P
Int J Cancer; 1995 Jul; 62(3):319-24. PubMed ID: 7628874
[TBL] [Abstract][Full Text] [Related]
7. Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell-independent induction of interleukin 2 responsiveness in T cells by epsilon-anti-CD3.
van Lier RA; Boot JH; Verhoeven AJ; de Groot ER; Brouwer M; Aarden LA
J Immunol; 1987 Nov; 139(9):2873-9. PubMed ID: 3117878
[TBL] [Abstract][Full Text] [Related]
8. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
9. Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region.
Sato K; Ohtomo T; Hirata Y; Saito H; Matsuura T; Akimoto T; Akamatsu K; Koishihara Y; Ohsugi Y; Tsuchiya M
Hum Antibodies Hybridomas; 1996; 7(4):175-83. PubMed ID: 9140729
[TBL] [Abstract][Full Text] [Related]
10. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
Bortoletto N; Scotet E; Myamoto Y; D'Oro U; Lanzavecchia A
Eur J Immunol; 2002 Nov; 32(11):3102-7. PubMed ID: 12385030
[TBL] [Abstract][Full Text] [Related]
11. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD3:anti-IL-2 receptor bispecific monoclonal antibody. Targeting of activated T cells in vitro.
MacLean JA; Su Z; Guo Y; Sy MS; Colvin RB; Wong JT
J Immunol; 1993 Feb; 150(4):1619-28. PubMed ID: 8432997
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes.
Malviya G; D'Alessandria C; Bonanno E; Vexler V; Massari R; Trotta C; Scopinaro F; Dierckx R; Signore A
J Nucl Med; 2009 Oct; 50(10):1683-91. PubMed ID: 19759100
[TBL] [Abstract][Full Text] [Related]
14. Induction of NK-like activity in T cells by IL-2/anti-CD3 is linked to expression of a new antitumour receptor with specificity for acetylated mannose.
Zollner TM; Zhu HG; Anderer FA
Anticancer Res; 1993; 13(4):923-30. PubMed ID: 8352560
[TBL] [Abstract][Full Text] [Related]
15. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
[TBL] [Abstract][Full Text] [Related]
16. Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys.
Co MS; Baker J; Bednarik K; Janzek E; Neruda W; Mayer P; Plot R; Stumper B; Vasquez M; Queen C; Loibner H
Cancer Res; 1996 Mar; 56(5):1118-25. PubMed ID: 8640770
[TBL] [Abstract][Full Text] [Related]
17. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
[TBL] [Abstract][Full Text] [Related]
18. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR
Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231
[TBL] [Abstract][Full Text] [Related]
19. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
20. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]